(R)-3-氨基-1-苯基-1-丙醇 | 138750-31-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (R)-3-氨基-1-苯基-1-丙醇
• 英文名称: (1R)-3-amino-1-phenyl-1-propanol
• 英文别名: (R)-3-amino-1-phenyl-propan-1-ol；(R)-1-phenyl-3-amino-1-propanol；(R)-3-amino-1-phenyl-1-propanol；(R)-3-amino-1-phenylpropan-1-ol；(R)-3-phenyl-3-hydroxypropylamine；(R)-3-amino-1-phenylpropanol；(1R)-3-amino-1-phenylpropan-1-ol
• CAS: 138750-31-9
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: PHIYHIOQVWTXII-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  (R)-3-氨基-1-苯基-1-丙醇 在 lithium aluminium tetrahydride 、 碳酸氢钠 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 生成 盐酸托莫西汀
  参考文献：
  名称：

  制备对映体纯的去甲氟西汀，氟西汀和托莫西汀的简便方法

  摘要：

  描述了一种方便的合成诺氟西汀，氟西汀和托莫西汀的对映异构体的方法。所有最终产物均来自共同的中间体3-苯基-3-羟丙胺。

  DOI：

  10.1016/s0040-4039(00)76212-5
• 作为产物：
  描述：

  3-羟基苯甲酸乙酯 在 盐酸 、 正丁基锂 、 甲酸 、 (S,S)-N-(对甲苯磺酰)-1,2-二苯乙烷二胺(对异丙基苯)氯化钌(II) 、 dimethyl sulfide borane 、 palladium 10% on activated carbon 、 1,3-双(二苯基膦)丙烷 、 氢气 、 palladium diacetate 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， -78.0~90.0 ℃ 、344.75 kPa 条件下， 反应 82.5h， 生成 (R)-3-氨基-1-苯基-1-丙醇
  参考文献：
  名称：

  US2014/275043

  摘要：

  公开号：

文献信息

• Pharmaceutically active pyrrolidine derivatives as bax inhibitors
  申请人：——

  公开号：US20030171309A1

  公开（公告）日：2003-09-11

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR<6>R<7>, NOR<6>, NNR<6>R<7>; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NR<8>R<9> or represents a heterocyclic residue having the formula (II) wherein Q is NR<10>, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及新的取代吡咯烷衍生物的化学式(I)。所述化合物通常用作药用活性化合物。具体来说，化学式(I)的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用处。所述吡咯烷衍生物显示出对细胞死亡促进子Bax和/或导致Bax激活途径的调节作用，最显著地是下调至抑制活性，并因此允许阻止细胞色素(c)的释放。本发明还涉及新的具有药用活性的取代吡咯烷衍生物，以及它们的制备方法，其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群；A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2-、—SO2NH—；—CH2-；B是一个群—(C═O)—NR<8>R<9>或代表具有化学式(II)的杂环残基，其中Q是NR<10>、O或S；n是选自0、1或2的整数；Y、Z和E与它们连接的两个碳共同形成一个5-6成员芳香族或杂芳族环。
• Novel phosphorus-containing prodrug
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP1634886A3

  公开（公告）日：2006-03-29

  Novel cyclic phosphoramidate prodrugs of parent drugs MH of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

  新型循环磷酰胺酯前药，其父药物MH的化学式I 描述了它们在药物输送到肝脏中的应用，它们在增强口服生物利用度中的应用，以及它们的制备方法。
• Pharmaceutically active pyrrolidine derivatives
  申请人：——

  公开号：US20030212012A1

  公开（公告）日：2003-11-13

  The present invention is related to pyrrolidine derivatives of formula (I). Said 1 compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
• Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin
  申请人：Baumgarten Wolfgang

  公开号：US20060009533A1

  公开（公告）日：2006-01-12

  The present invention relates to an improved process for preparing enantiomerically pure 3-hydroxy-3-phenyl-propylamines on an industrial scale using asymmetrical hydrogenation as a key step and optionally a special sequence of subsequent steps, using a catalyst system consisting of rhodium and chiral 4-(dicyclohexylphosphino)-2-(diphenyl-phosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine.

  本发明涉及一种改进的工业规模下制备对映纯3-羟基-3-苯基-丙胺的方法，其关键步骤是使用不对称氢化，并可选地采用一系列特殊的后续步骤，使用由铑和手性4-(二环己基膦基)-2-(二苯基膦基甲基)-N-甲基氨基甲酰基吡咯烷组成的催化系统。
• An asymmetric dihydroxylation route to enantiomerically pure norfluoxetine and fluoxetine
  作者：Rajesh Kumar Pandey、Rodney A. Fernandes、Pradeep Kumar

  DOI：10.1016/s0040-4039(02)00842-0

  日期：2002.6

  An efficient, practical asymmetric synthesis of (R)-norfluoxetine 1 and (R)-fluoxetine 2 has been achieved. The synthetic strategy features a Sharpless asymmetric dihydroxylation (SAD) route to the common building block 1,3-amino alcohol 9, from which (R)-norfluoxetine, (R)-fluoxetine and other related analogs can be synthesized.

  （R）-去氟西汀1和（R）-氟西汀2的有效，实用的不对称合成已经实现。合成策略的特征是通向通用构件1，3-氨基醇9的Sharpless不对称二羟基化（SAD）路线，从中可以合成（R）-去氟西汀，（R）-氟西汀和其他相关类似物。